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Some women who report to a hospital or arthritis clinic note exacerbation of rheu- 
matic complaints and develop serologic abnormalities while taking oral contracep 
tives. The current study concerns the detection of antinuclear antibodies, 
rheumatoid factor and C-reactive protein in normal women using these drugs. 
Prospective study of 82 women before and during oral contraceptive use permitted 
the detection of 4 who developed antinuclear antibodies, 9 who developed rheu- 
matoid factor and 30 who developed C-reactive protein after less than 1 year of 
drug use. The prevalence of positive tests was greater in a group o f  210 women 
who were using OC than that found in a group of 174 who had never used these 
drugs. None of these women developed rheumatic symptoms while using oral 
contraceptives. 
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Recently several authors have reported 
an association between the use of oral 
contraceptives and the exacerbation of rheu- 
matic complaints or the induction of au- 
toantibodies. The  prevalence of these ab- 
normalities has varied, dependent at least 
in part, upon the nature of the population 
of women studied. Three studies (1,2,3) 
dealing with patients seen in a clinic or 
hospital have described the occurrence of 
rheumatic symptoms, antinuclear anti- 
bodies, or LE cells during treatment with 
oral contraceptives. When the population 
group was apparently normal women 
studied at birth control clinics, few abnor- 
malities were found. Dubois and associates 
(4) tested the serum of 30 normal women 
for the presence of antinuclear antibodies 
(ANA), rheumatoid factor and LE cell 
phenomena, and concluded there was no 
evidence that oral contraceptives (OC) stim- 
ulated or induced autoantibodies. In  an- 
other study (5 ) ,  the prevalence of ANA in a 
group of 176 women was not increased; 
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however, the occurrence of positive tests 
for rheumatoid factor was increased during 
the use of oral contraceptives. 
The current study was undertaken in 
order to determine if the frequency and 
type of serologic abnormality detected in 
normal women seen at a birth control 
clinic during OC use differed from that 
observed in patients reporting to a hospital 
or arthritis clinic. To properly interpret 
test results obtained during use of oral 
contraceptive agents, knowledge of the pre- 
treatment status of the women was of criti- 
cal importance. In addition, duration of 
drug use and chemical composition of these 
sera used in the present study represent random 
samples from 121 women who ranged in age from 
17-39 years. The samples were selected from among 
a total of 3000 specimens included in a rheumatic 
disease investigation. Historic data on each of these 
women contained specific information regarding the 
use of OC. None of the 11 women with positive 
tests was using an 0C.t Oral contraceptives in use 
by the women of Group 1A and Group 2 contained 
a synthetic estrogen and a progestagen. Tabulation 
of drug type, chemical composition, and the num- 
ber of women using each, is listed in Table 2. 
Serum was harvested from whole blood and 
divided into several aliquots which were stored at 
-20°C without added preservative. Each specimen 
was thawed only once before the several laboratory 
determinations. Serial serum specimens from the 
same patient were tested simultaneously. 
agents has been reported to influence the Antinuclear antibodies were detected using a 
clinical results. Each of these factors has modification of the indirect immunofluorescent 
been evaluated in this study of healthy technic described by Friou (7). Four-micron liver 
sections from 2-month-old female Swiss Webster 
young who initiated therapy with mice were prepared daily in a cryostat and fixed in 
one of the currently available forms of oc. 100% acetone on uncoated microscope slides. Flu- 
orescein-conjugated horse antihuman globulin$ was 
employed. Adsorption of the antiglobulin with 
mouse-liver powder did not alter the specificity of MATERIALS AND METHODS 
Serum from 503 women between the ages of 16 its reactivity with positive or negative sera. Each 
and 47 was collected and assayed for the presence of serum specimen was tested at 1:1 and 1: lO serum 
antinuclear antibodies (ANA) , rheumatoid factor dilution. A serum specimen was considered positive 
(RF), LE cells, and C-reactive protein (CRP). In if it was reactive at 1:lO serum dilution. Positive 
Table 1 are listed certain of the characteristics of and negative control sera from the same individuals 
the three groups of women included in this study. were used throughout this study. 
Women in Groups 1 and 2 reported voluntarily Serum specimens were surveyed for rheumatoid 
between Oct 1968 and Jan 1970 to birth control factor activity using a latex-agglutination slide test.§ 
clinics of the Washtenaw County League for All sera that were positive or weakly reactive on 
Planned Parenthood and the University of Michi- slide test, as well as serum specimens from all 
gan. The first (blood specimen was collected at the women with positive tests for ANA were reassayed 
time of initial physical examination. Based upon for rheumatoid factor by the latex tube-test of 
history and physical findings, each woman was Singer and Plotz (8). Tests for RF were considered 
considered normal a t  the time of entrance into this positive if they were reactive at a serum dilution of 
study. Ten percent of the clinic patients refused to 1:40 or greater in the latex tube-test. C-reactive 
donate an initial blood specimen. Those beginning 
oral contraceptives for the first time were asked to 
return for follow-up 3 months after starting these 
drugs.. The women in Group 2 were taking OC at 
the time of the initial examination. The Group 3 
'Initial follow-up interval varied between 1 and 
12 months after starting OC and was: 1 month in 
4 women, two months in 10, three months in 34, 
four to 6 months in 27, seven months in 2, eight 
months in 3 and 10-12 months in 2. In 9 women, 
three or more specimens were available at approxi- 
mately 3, 6 and 9 or 12 months after starting OC. 
protein was measured by a capillary precipitation 
method using commercial antisera.11 Duplicate capil- 
lary tubes containing equal volumes of patients' 
+The women in Group 3 were representatire of 
the general population. Sera from these women 
has been collected as part of the Tecumseh Health 
Study. This comprehensive community study in- 
cluded a special investigation of rheumatic disease 
(6) ' 
$Progressive Laboratories, Baltimore, Md. 
WHyland Laboratories, Costa Mesa, Calif. 
IIBehringwerke, Woodbury, NY. 
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Table 1. Characterization of Study Groups 
Age Months of OC use 
No.of White 
Group patients Mean Range Range Mean race 
1. Never on OC* 174 20.9 16-40 0 0 90% 
Follow-up on OC 82 20.9 18-35 1-12 4 95% 
Follow-up not available 92 20.9 16-40 85% 
2. On OC at t ime of init ial exam* 210 24.9 17-47 3-84 28 85% 
3. Community study 119t 17-39 100% 
* Birth control clinic 
t Two of the total number of 121 were excluded due to a positive test for ANA and concurrent use of OC 
Table 2. Oral Contraceptives Taken by  Study Patients 
Corn posit ion Proprietary name Group 1A Group 2 
Combination 
norethindrone, 2 rng and 
mestranol, 0.1 rng 
norethindrone, 1 rng and 
mestranol, 0.05 m g  
norethindrone, 1 rng and 
rnestranol, 0.08 rng 
norethindrone acetate, 1 rng and 
ethinyl estradiol, 0.05 rng 
norethynodrel, 2.5 rng and 
rnestranol, 0.10 rng 
ethynodiol diacetate and 
rnestranol, 0.10 rng 
norgestrel, 0.5 rng and 
ethinyl estradiol, 0.05 m g  
chlormadinone acetate 2 rng 
rnestranol 0.08 m g  
Other oral contraceptives* 
Sequential 
Ortho-Novurn 2 rng 
Norinyl 
Ortho-Novum 1 rng 
Ortho-Novurn 1/80 























* Group 2-Combination drugs: nonrethynodrel2.5 rng, rnestranolO.075 rng (Enovid 5 rng) -4; rnedroxy 
progesterone 10 mg, ethinyl estradiol 0.05 rng (Nor1utin)-1: rnedroxyprogesterone 10.0 mg, ethinyl estra- 
diol .05 rng (Provest)-1;-Sequential Drugs: norethindrone 2 rng, mestranolO.08 mg, (Ortho-Novum SQ)-4: 
dirnethesterone 25 rng, ethinyl estradiol 0.1 rng (0racon)-1. 
serum and 5 %  albumin-saline were included to rabbits was assayed for purity by immunoelectro- 
differentiate between cryoprecipitation and the phoresis and immunodiffusion. Test serum diluted 
presence of CRP. Tests for LE cell were performed 1:40 was applied to immunodiffusion plates contain- 
on serum by a two-stage indirect method (9) . ing 2% antiserum in 1% agar. Immunodiffusion 
Immunoglobulin levels were assayed by radial plates for IgA and IgM were of commercial origin: 
immunodiffusion (10) . Monovalent antisera to hu- Standardized human serum,* containing known 
man IgG was prepared in this laboratory as de- 
scribed by Fahey (11). The  antisera raised in +Behringwerke, Woodbury, NY. 
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concentrations ot lgti, IgA and IgM, was assayed at 
three dilutions on each immunodiffusion plate. 
Normal range of values for adults 1843  years of 
age, established in this laboratory are: IgG, 7.0- 
16.0; IgM, 0.5-2.3; IgA, 0.9-2.6 mg/ml. 
The statistical analysis of these data employed 
the chi-square test for comparison of different 
groups of women (12) .  The probability values 
calculated in prospective studies on the same wom- 
en, were obtained by comparing correlated percent- 
ages and from the Q test, a special chi-square test 
for matched samples (13 ) .  
RESULTS 
Eighty-two of 174 Group 1 women who 
had not previously taken OC returned and 
donated a second blood specimen 1-12 
months after starting these drugs. The  re- 
sults of the prospective studies in this 
group of women (Group 1A) are presented 
in Table 3. Seven women had positive tests 
for ANA before therapy and all remained 
positive during drug use. Four additional 
women with negative ANA tests prior to 
treatment developed positive tests for ANA 
after 1, 2, 7 and 8 months, respectively. It is 
of interest that these 4 women were taking 
oral contraceptive combinations that con- 
tained at least 80 g m  of Mestranol per 
tablet,* however, this was not a statistically 
significant association. Rheumatoid factor 
was detected in the serum of 3 women 
before. and in 9 more women after institu- 
tion of OC. In  these rheumatoid factor 
converters, no single drug combination pre- 
dominated (Ovulin 21, 2; Ortho-novum 
1/80, 4; Ovral, 2; Norlestrin, 1). They had, 
as a group, used oral contraceptives for a 
longer period (mean 6 months) than did 
the women who remained seronegative 
(mean 4 months). The  titer of R F  did not 
change in the 3 women who were positive 
before starting OC. C-reactive protein first 
appeared in the serum of 30 patients dur- 
fOrtho Novum (3), Ortho Pharmaceutical Corp., 
Raritan, NY and Ovulen 21 ( I ) ,  G. D. Searle & Co, 
Chicago, 111. 
Table 3. Serologic Abnormalities in 82 
Women (Group 1A) Before and During Use 
of Oral Contraceptives 
Before OC On OC 
Serologic % % 
test No. positive No. positive P 
ANA* 7 8 . 5  11 13.4 <0.02 
R F t  3 3.7 12 14.6 <0.01 
CRP 12 14.6 39 47.6 <0.01 
LE cell 0 0  0 0  
* 1:10 serum dilution 
t 1:40 serum dilution 
ing use of OC, while 3 of 12 patients with 
positive tests before therapy became nega- 
tive during treatment. LE cell phenomenon 
was not detected in any patient. Serologic 
conversion of each of these laboratory tests 
during the use of OC was significant 
(P<O.O2 or 0.01). 
In the group of 82 women who were 
studied prospectively, the occurrence of 
one serologic abnormality increased the 
tendency for the occurrence of additional 
serologic abnormalities (Table 4). Seven- 
teen of the 82 women accounted for all 
positive tests for ANA or RF that were 
found during treatment with OC. In  these 
women, the prevalence of positive tests for 
CRP was much greater (70y0) than that 
seen in seronegative Group 1A women (24 
of 64 or 37%). Serum concentrations of 
IgG, IgM and IgA in seropositive women 
were measured before and during use of 
OC (Table 4). A moderate elevation in 
serum IgM level was found in 5 women 
before treatment and in 2 others during 
treatment with OC. Three of the 4 patients 
who developed ANA had increased serum 
concentrations of IgM before drug use. 
These elevations were not sustained during 
drug administration. Four of the 9 women 
who developed positive tests for R F  had 
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Table 4. Serologic Abnormalities (Group 1A) Before and During Use of Oral Contraceptives 
Age Pre On Pre On Pre On Pre On Pre 
19 0 + 0 1280 0 + 11.2 9.9 0.9 
20 0 + 0 640 0 + 7.3 7.8 4.0 
26 0 + 0 0 + + 13.8 12.6 2.7 
35 0 + 0 0 + + 12.0 11.0 2.6 
4 Seronegative women developed A N A  
5 Seronegative women developed RF 
20 0 0 0 320 0 + 9.5 9.7 1.3 
20 0 0 0 40 0 + 6.8 9.5 1.8 
21 0 0 0 40 0 0 8.1 9.1 1.5 
23 0 0 0 1280 0 + 9.0 9.1 1.9 
25 0 0 0 640 0 0 11.0 11.0 1.6 
7 women ANA positive before and during OC use 
18 + + 1280 1280 0 + 11.9 10.3 1.5 
19 + + 0 0 0 0 9.2 8.8 2.0 
20 + + 2560 2560 + + 10.6 9.3 3.0 
20 + + 0 640 + 0 8.2 8.0 2.0 
20 + + 0 0 0 + 7.0 6.9 2.2 
21 + + 0 320 + + 11.2 10.8 3.0 
28 + + 0 0 + + 15.4 10.4 1.7 
1 woman RFpositive before and during OC use 
22 0 0 640 640 + + 6.7 6.5 1.3 
On Pre On 
2.0 2.0 1.7 
3.6 1.2 1.1 
2 .o 2.6 2.3 
2.0 1.2 1.6 
1.6 1.5 1.5 
1.9 1.0 1.1 
2.4 1.0 1.0 
2.2 1.7 1.6 
1.4 2.8 2.6 
1.3 1.0 1.9 
1.6 3.3 2.6 
4.3 2.1 1.4 
2.3 0.9 1.0 
1.9 1.8 1.4 
3.0 1.1 1.0 
1.7 2.0 1.5 
1.0 1.5 1.2 
* ANA positive at 1:lO serum dilution 
t RF reciprocal t iter 
increased serum IgM levels during drug 
therapy. No consistent alteration in serum 
IgA concentration was noted. A mean de- 
crease in serum IgG concentration from 
10.0 2 0.60 (mg/ml f SEM) to 9.5 2 0.51 
occurred in seropositive women during 
treatment with OC. By contrast, in the 5 
women whose only abnormality during 
treatment was the detection of RF, mean 
serum concentration of IgG increased from 
8.8 2 0.69 to 9.6 * 0.33. Alterations in 
mean IgG serum concentration were com- 
pared with that observed in 12 seronegative 
women from Group IA, matched for age 
and drug use with the seropositive group. 
The  mean serum IgG level in the seronega- 
tive women was initially si<gnificantly lower 
(7.6 2 0.46) than in the seropositive wom- 
en, and decreased slightly during OC use to 
7.3 f 0.43 mg/ml. The  observed alterations 
in immunoglobulin concentration did not 
correlate with positive tests for CRP. 
In  Table 5, the mean concentrations of 
IgG, IgM and IgA in the 17 seropositive 
women of Group 1A before and during OC 
treatment is summarized and compared 
with the findings in the 35 women of 
Group 2 who had positive tests for ANA or 
RF while taking OC. None of the seroposi- 
tive women in Group 1A or Group 2 had 
an overt form of dysgammaglobulinemia. 
Six seropositive women of Group 2 had 
modestly increased IgM concentrations 
while taking OC (>2.3 mg/ml). None of the 
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table 5. Immunoglobulin Levels in Sera tests for ANA increases with chronologic 
age. of Women Positive for ANA or RF 
Number of women 
Observed Within Below Above 
(mean normal normal normal 
Group f SE*) ranget range range 
1A pre-OC 
(17 of 82) 
IgG 10.0f 0.60 15 2 0 
IgM 2 . l f  0.20 12 0 5 
I gA 1 . 6 f  0.18 15 0 2 
1A on OC 
(17 of 82) 
IgG 9 . 4 f  0.38 15 2 0 
IgM 2 . 2 f  0.21 12 0 5 
I gA 1 . 6 f  0.14 17  0 0 
2 on OC 
(35 of 210) 
IgG 1 0 . 0 f  0.34 34 1 0 
IgM 1 . 7 f  0.11 29 0 6 
I gA 1.8&0.11 30 2 3 
* Observed mean (mg/ml) f standard error of 
the mean for all seropositive women 
t Normal range of values for immunoglobulins 
in adults (18-43 years of age) as established in 
this laboratory are: IgG 7.0-16.0; IgM 0.5-2.3; 
IgA 0.9-2.6 rng/ml 
women in Group 1A or Group 2 developed 
specific rheumatic complaints during treat- 
ment with OC. 
In Table 6, the prevalence of all positive 
tests for ANA in Group 1 and in Group 2 
is compared by chronologic age increments 
with women in Group 3. This latter group, 
matched for age, was selected at random 
from a total of 3000 serum specimens col- 
lected as a part of a community health 
survey. This study was required since the 
prevalence of positive tests for ANA in 
women 15-45 years of age has not previous- 
ly been reported. Cross-comparison of the 
three groups failed to demonstrate a statis- 
tically significant difference in the preva- 
lence of positive tests for ANA. The data 
does suggest that the frequency of positive 
When all pretreatment sera from Group 
1 are compared with on-treatment sera 
from Group 2 women, the percentage of 
positive tests for ANA, RF and CRP is 
greater in Group 2 women (Table 7). 
When group comparisons were made, only 
the increase in positive tests for C-reactive 
protein was statistically significant (P<.05). 
Women in Group 2 had taken OC for 
longer periods of time (mean 28 months) 
than had women in Group 1A (mean 4 
months). In Group 2 females, age, drug 
type or duration of use of drug could not 
be correlated with the occurrence of posi- 
tive tests for ANA, RF or CRP. In addi- 
tion, the titers of RF in Group 2 women 
were comparable to those observed in indi- 
vidual patients of Group 1 (1:40-1:2560). 
No one pattern of nuclear fluorescence pre- 
dominated in any group. The pretreatment 
prevalence of ANA in Group 1 women was 
the same as that observed in a subgroup of 
29 Group 3 women with the same mean 
chronologic age (20.9 years). Although 
Group 2 women had a higher number of 
positive tests for ANA (10%) than a 
subgroup of 24 women from Group 3 
(4.2%) with the same mean age (24.9 
years), the difference was not statistically 
significant. These results emphase the im- 
portance of the prospective data obtained 
during the Study of Group 1A women, in 
whom a statistically significant number of 
positive tests for ANA, RF and CRP de- 
veloped. 
DISCUSSION 
Several drugs will induce autoantibodies 
in humans (14). The prospect that synthet- 
ic estrogens or progestagens found in oral 
contraceptives might induce similar sero- 
logic changes has been suggested by two 
recent reports. Schleicher (2) noted disap 
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Table 6. Prevalence of Positive Tests for ANA by Age in Group 1, 2, 3 
Group 1, never used OC Group 2, using OC Group 3 
~ ___ _- - 
Age No. positive/ No. positive/ No. positive/ 

























































TOTAL POSITIVE/TOTAL TESTED 111174 211210 111119 
pearance of LE cell phenomena from the 
sera of 10 women after withdrawal of oral 
contraceptives. Bole (3) reported 8 women 
with early rheumatic complaints who had 
positive LE cell and/or ANA tests while 
taking oral contraceptives. When the pa- 
tients stopped these drugs, LE cell phe- 
nomena and ANA frequently disappeared 
from their sera and rheumatic symptoms 
diminished. Spiera and Plotz (15) noted a 
relationship between the use of OC and the 
presence of rheumatic symptoms in 22 
Table 7. Comparison of the Prevalence of 
Positive Serologic Tests Between Women 
of Groups 1 , 2  and 3 
Group 1 Group 2 
Sero- neverOC on OC Group3 
test No. % No. % No. % P 
logic ___ ____ _-__ 
ANA 11 ( 6.3) 2* (6.9) NS 
21 (10.0) l t  (4.2) NS 
RF 8 ( 4 . 6 )  16 ( 7.6) NS 
CRP 25 (14.4) 49 (23.3) <0.05 
Total 174 210 
* Two of a subgroup of 29 Group 3 women with 
t One of a subgroup of 24 Group 3 women with 
same mean age as Group 1 
same mean age as Group 2 
women. They did not detect any serologic 
abnormalities in these women during use 
of OC. Pretreatment sera were not exam- 
ined by Schleicher or Bole, therefore, in- 
duction of autoantibodies was inferred 
from the disappearance of serologic abnor- 
malities after withdrawal of OC. These 
observations concerned women presenting 
to the physician with early rheumatic com- 
plaints and gave no information as to the 
frequency of occurrence of abnormal tests 
for ANA, RF or LE phenomenon in 
asymptomatic women who were taking OC. 
As discussed prevously, two preliminary 
reports (4,5) that dealt with the occurrence 
of positive tests for ANA, LE cells or RF 
in apparently healthy young women while 
they were receiving OC have given 
disparate results. Another study (16) de- 
scribes the development of rheumatic signs 
and symptoms in a large birth control 
clinic population during the use of oral 
contraceptives. In this series of 3014 wom- 
en (90% black race), the incidence of rheu- 
matoid arthritis (definite, probable, pos- 
sible) increased from 9 per 3014 to 20 per 
3014 over a mean period of 12 months of 
oral contraceptive use. Based strictly upon 
the low prevalence of rheumatoid arthritis 
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in OC users at the end of the study, the 
author concluded that OC did not influ- 
ence rheumatic complaints. However, com- 
pared to the age-dependent increase in 
prevalence of rheumatoid arthritis report- 
ed in other population surveys (6, 17), this 
rate far exceeds the annual increment at- 
tributed solely to patient age. Detailed 
serologic studies on this group of women 
were not reported. I t  was noted that 2 of 
the 7 women with sickle cell anemia had 
positive tests for rheumatoid factor while 
taking OC. 
Population and family studies have 
demonstrated that a small percentage of 
normal women will have autoantibodies 
(18), rheumatoid factor (19), and ANA 
(20), in the absence of rheumatic disease. 
In  the Tecumseh Community Health Study 
(6), (the population from which Group 3 of 
this study was selected), 2% of women 
20-29 years of age had rheumatoid factor 
detected by latex tube-test. This figure in- 
creased in 3.8y0 for women 30-39 years of 
age. Depending upon the methods em- 
ployed for detection, 0-25y0 of normal 
women may have ANA. Svec (21) has re- 
cently reported an increase in the preva- 
lence of these autoantibodies in women 
over 60 years of age. The  value reached 
25y0 in women past the age of 60. In  the 
current study, an established, sensitive 
method for the detection of ANA demon- 
strated that the prevalence of positive tests 
increased in women between 17 and 39 
years of age. Only in Group 1A women 
(mean age 21 years), where their pretreat- 
ment serologic status was known, and OC 
treatment interval short, could a significant 
association between OC use and serologic 
abnormalities be established. I t  is impor- 
tant to note that the prevalence of abnor- 
mal serologic tests in Group 1 women prior 
to OC treatment was higher than that 
reported in other population studies: 6% 
had ANA, 470 RF, and 14y0 CRP. It is also 
of interest that 4 of 11 serologic converters 
had pretreatment elevations of serum IgM 
levels as did 5 of the 8 women previously 
reported by Bole (3). However, no overt 
example of dysgammaglobulinemia was 
identified in any of these women. These 
findings suggest that apparently healthy 
young women reporting to a birth control 
clinic for contraceptive advice are not 
necessarily representative of all women in 
the child bearing years. 
The composition and dose of the oral 
contraceptive may have influenced the in- 
duction of antinuclear antibodies. All 4 
ANA converters were using a combination 
estrogen-progestagen that contained at 
least 80 pg Mestranol per tablet. This syn- 
thetic estrogen in similar or high dosage 
was also used by the symptomatic patients 
with positive tests for ANA previously re- 
ported by Bole and associates (3). In  con- 
trast to the preliminary observation of 
McKenna (5) that positive tests for RF 
correlated with the use of a Norethindrone- 
Mestranol combination, RF converters in 
the current study had used several different 
drug combinations. Current trends are 
toward use of oral contraceptives contain- 
ing smaller amounts of synthetic estrogen 
in view of the statistical correlation of high 
estrogen content with thromboembolic dis- 
ease (22). Although few women were 
studied, note should be taken of Dubois’ 
observation (4) that R F  or ANA was not 
detected in 8 women who used an OC 
containing only progestogen (chlormad- 
inone). 
CRP has been reported to appear in the 
serum of 72Y0 of normal women when they 
use OC (23). In  the current study, the high 
frequency of CRP induction permitted sta- 
tistically significant conclusions to be 
drawn from group comparisons (Group 1 
and Group 2) as well as from prospective 
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study of individual patients (Group 1A). 
There are major statistical limitations im- 
posed on group comparisons when an 
event occurs infrequently (24). By contrast, 
prospective study of 82 women before and 
during oral contraceptive therapy allowed 
identification of 4 who developed ANA, 9 
who developed rheumatoid factor, and 30 
who developed CRP within one year after 
starting these drugs, and these associations 
were found to be significant. 
None of the women studied before or 
during OC use developed symptoms of rheu- 
matic disease. Long-term follow-up will 
be required to determine if women with 
autoantibodies in their serum initially or 
subsequent to oral contraceptive therapy 
have latent or subclinical autoimmune dis- 
ease. Dissociation of serologic abnormalities 
from the observed presence of clinical dis- 
ease is well recognized (25). Induction of 
serologic abnormalities in healthy young 
women who are taking OC should also be 
viewed from this perspective. However, rec- 
ognition that oral contraceptives may cause 
positive reactions for ANA, RF or CRP is 
important to the proper use of these tests 
in clinical differential diagnosis of rheu- 
matic disease. 
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